Key statistics
On Friday, Avalo Therapeutics Inc (AVTX:NAQ) closed at 9.72, 146.07% above the 52 week low of 3.95 set on Jan 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.51 |
---|---|
High | 9.72 |
Low | 9.08 |
Bid | 9.40 |
Offer | 9.79 |
Previous close | 9.37 |
Average volume | 11.10k |
---|---|
Shares outstanding | 1.03m |
Free float | 863.96k |
P/E (TTM) | -- |
Market cap | 10.05m USD |
EPS (TTM) | -63.82 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Avalo Announces Participation in September Investor Conferences
- Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
- Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Avalo Reports 2023 Financial Results and Provides Business Updates
- Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
More ▼